If this doesn’t work well enough to decrease LDL, doctors may increase the dosage to a 420-mg dose (three 140-mg injections) every 2 weeks. Here are some common questions related to Repatha’s ...

Repatha 140 mg every 2 weeks or 420 mg alone 54% to 56% Repatha 140 mg every 2 weeks or 420 mg monthly with statins and some also taking ezetimibe 47% to 63% Taking a high-dose statin can possibly ...

Either 140 mg once every 2 weeks or 420 mg once monthly, administered subcutaneously [Repatha package insert;2e] In adult and pediatric patients with HoFH aged 10 years or older: a subcutaneous ...

The study, in which patients were given either monthly Repatha 420 mg or placebo subcutaneous injections, showed that Repatha modifies the underlying process of atherosclerosis, a major cause of ...

the FDA noted that both dosing regimens (140 mg once every 2 weeks/Q2W and 420 mg once monthly) of Repatha resulted in a statistically significant reduction in LDL-C (“bad” cholesterol ...

THOUSAND OAKS, Calif., March 18, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Repatha® (evolocumab) cognitiv ...

BETHESDA, MD — The US Food and Drug Administration (FDA) has approved the evolocumab (Repatha, Amgen ... can self-administer every 2 weeks or 420 mg once a month. The Pushtronex system is ...

Patients were on an optimized statin therapy and randomized to receive Repatha at a 140 mg dose every 2 weeks or a 420 mg dose monthly or a placebo every 2 weeks or monthly. “These FOURIER ...

Repatha is given as a 140 mg injection every other week or as a monthly injection of 420 mg. Amgen said the wholesale cost of the drug will be $14,100 a year for the every other week injection.

When Repatha was first approved by the FDA in August 2015, the dosing was 140 mg every two weeks or 420 mg once monthly. Until the approval of the single-dosing option, the 420-mg monthly dose ...

YUKAWA-2, a pivotal Phase 3 study in Japanese patients with high cardiovascular risk and high cholesterol, demonstrated that subcutaneous Repatha 140 mg every two weeks or 420 mg every four weeks ...

The PCSK9 inhibitor regimens of Repatha 140 mg once every two weeks (Q2W) or 420 mg once monthly (QM) and alirocumab 150 mg Q2W were the most effective for reducing LDL-C levels when added to statins.